112,631 Shares in Vaxcyte, Inc. $PCVX Bought by WCM Investment Management LLC

WCM Investment Management LLC bought a new position in Vaxcyte, Inc. (NASDAQ:PCVX) in the 1st quarter, Holdings Channel.com reports. The fund bought 112,631 shares of the company’s stock, valued at approximately $6,190,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Smartleaf Asset Management LLC raised its holdings in shares of Vaxcyte by 156.2% during the fourth quarter. Smartleaf Asset Management LLC now owns 597 shares of the company’s stock worth $27,000 after purchasing an additional 364 shares during the period. Caitong International Asset Management Co. Ltd raised its holdings in shares of Vaxcyte by 1,463.4% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 641 shares of the company’s stock valued at $30,000 after buying an additional 600 shares during the last quarter. EverSource Wealth Advisors LLC raised its stake in Vaxcyte by 33.0% during the 4th quarter. EverSource Wealth Advisors LLC now owns 741 shares of the company’s stock valued at $34,000 after acquiring an additional 184 shares in the last quarter. Capital Advisors Ltd. LLC bought a new stake in shares of Vaxcyte during the first quarter valued at about $58,000. Finally, Allworth Financial LP raised its position in shares of Vaxcyte by 148.9% during the 3rd quarter. Allworth Financial LP now owns 1,222 shares of the company’s stock worth $44,000 after buying an additional 731 shares in the last quarter. 96.78% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on PCVX shares. Zacks Research lowered Vaxcyte from a “hold” rating to a “strong sell” rating in a report on Tuesday, July 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vaxcyte in a research note on Monday, July 6th. Finally, Wall Street Zen lowered Vaxcyte from a “sell” rating to a “strong sell” rating in a research report on Tuesday, April 28th. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, Vaxcyte currently has an average rating of “Hold” and an average target price of $86.00.

Vaxcyte Price Performance

Vaxcyte stock opened at $55.50 on Tuesday. The company has a market capitalization of $8.01 billion, a price-to-earnings ratio of -8.07 and a beta of 1.22. The company’s fifty day moving average price is $52.37 and its two-hundred day moving average price is $54.36. Vaxcyte, Inc. has a one year low of $29.08 and a one year high of $65.00.

Vaxcyte (NASDAQ:PCVX) last posted its earnings results on Wednesday, May 6th. The company reported ($2.30) earnings per share for the quarter, missing the consensus estimate of ($1.74) by ($0.56). During the same period in the previous year, the business posted ($1.04) earnings per share. As a group, sell-side analysts anticipate that Vaxcyte, Inc. will post -7.91 earnings per share for the current year.

Insider Activity

In other news, CEO Grant Pickering sold 22,461 shares of the business’s stock in a transaction on Thursday, June 18th. The shares were sold at an average price of $52.50, for a total value of $1,179,202.50. Following the completion of the sale, the chief executive officer directly owned 474,703 shares in the company, valued at approximately $24,921,907.50. The trade was a 4.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew Guggenhime sold 10,000 shares of the company’s stock in a transaction on Monday, July 6th. The stock was sold at an average price of $57.28, for a total transaction of $572,800.00. Following the sale, the chief financial officer directly owned 104,395 shares of the company’s stock, valued at approximately $5,979,745.60. This represents a 8.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 75,448 shares of company stock valued at $4,091,197 over the last 90 days. 3.30% of the stock is currently owned by company insiders.

Vaxcyte Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.